Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Stoke Therapeutics, Inc.    STOK


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Stoke Therapeutics : Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares

11/25/2020 | 09:56am EST

BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters' option to purchase additional shares, at a price to the public of $39.00 per share.

The net proceeds from the offering were approximately $105.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC acted as joint book-running managers in the offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. acted as passive bookrunners in the offering.

Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and other general corporate purposes.

The public offering was made pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (the 'SEC'). This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; from Cowen and Company, LLC c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (833) 297-2926, or by emailing PostSaleManualRequests@broadridge.com; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com. Electronic copies of the prospectus supplement and accompanying prospectus are available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding its expectation of market conditions, use of proceeds and Stoke's plan to develop its precision medicine platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Stoke believes that the expectations reflected in such forward-looking statements are reasonable, Stoke cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, market conditions, the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described under the heading 'Risk Factors' in documents Stoke files from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Stoke specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.


Dawn Kalmar

Tel: 781-303-8302

Email: dkalmar@stoketherapeutics.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG -0.20% 12.325 Delayed Quote.8.33%
STOKE THERAPEUTICS, INC. 1.91% 66.57 Delayed Quote.7.49%
01/11STOKE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regula..
01/04STOKE THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confer..
2020SECTOR UPDATE : Health Care Stocks Hang on for Small Advance
2020STOKE THERAPEUTICS : Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN..
2020STOKE THERAPEUTICS : Canaccord Adjusts Stoke Therapeutics' Price Target to $72 F..
2020STOKE THERAPEUTICS : HC Wainwright Starts Stoke Therapeutics at Buy With $70 Pri..
2020STOKE THERAPEUTICS : Needham Adjusts Stoke Therapeutics' Price Target to $56 Fro..
2020CORRECTION : Stoke Therapeutics Reports Data From Observational Study of Patient..
2020STOKE THERAPEUTICS : to Present at the Needham Virtual Epilepsy & Pain – S..
2020Stoke Therapeutics Reports Positive Data From Study of STK-001 in Patients Wi..
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -52,1 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -42,6x
Yield 2020 -
Capitalization 2 412 M 2 412 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 56
Free-Float 96,4%
Duration : Period :
Stoke Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STOKE THERAPEUTICS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Average target price 57,63 $
Last Close Price 66,57 $
Spread / Highest target 8,16%
Spread / Average Target -13,4%
Spread / Lowest Target -36,9%
EPS Revisions
Managers and Directors
Edward M. Kaye Chief Executive Officer & Director
Seth L. Harrison Chairman
Huw M. Nash Chief Operating & Business Officer
Stephen J. Tulipano Chief Financial Officer
Barry S. Ticho Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
SEAGEN INC.6.06%33 601